Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial-Reference-Cited by-同舟云学术

Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial

Published:2019-07-04 Issue:2 Volume:30 Page:313-320
ISSN:1439-7595
Container-title:Modern Rheumatology
language:en
Short-container-title:Modern Rheumatology

Author:

Tanaka Yoshiya¹,Bass Damon²,Chu Myron²,Egginton Sally³,Ji Beulah⁴,Roth David²

Affiliation:

1. The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health Japan, Kitakyushu, Japan;

2. Immuno-Inflammation, GSK, Philadelphia, PA, USA;

3. Biostatistics, GSK, Stevenage, UK;

4. R&D Clinical Development, GSK, Uxbridge, UK

Funder

GlaxoSmithKline

Publisher

Oxford University Press (OUP)

Subject

Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14397595.2019.1630897

Reference32 articles.

1. Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines

2. Current and novel therapeutics in the treatment of systemic lupus erythematosus

3. EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints: Table 1

4. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Usefulness of Belimumab in Adult Patients With Systemic Lupus Erythematosus Evaluated Using Single Indexes: A Meta-Analysis and Systematic Review;Current Therapeutic Research;2024

2. The Safety and Efficacy of Rituximab and Belimumab in Systemic Lupus Erythematosus: A Systematic Review;Cureus;2023-06-21

3. Determinants of neuropsychiatric flares in patients with systemic lupus erythematosus: results from five phase III trials of belimumab;Rheumatology;2023-05-25

4. Efficacy and safety of belimumab therapy in lupus nephritis: a systematic review and meta-analysis;Renal Failure;2023-05-17

5. Belimumab: A BAFF-specific Inhibitor for the Treatment of Systemic Lupus Erythematosus and Lupus Nephritis;Rheumatology;2022